Patents Assigned to Abbott Healthcare Products B.V.
-
Publication number: 20140011775Abstract: This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis.Type: ApplicationFiled: September 11, 2013Publication date: January 9, 2014Applicant: Abbott Healthcare Products B.V.Inventors: Arnold van Loevezijn, Wouter I. Iwema Bakker, Axel Stoit, Agatha A.M. Rensink, Jennifer Venhorst, Martina A.W. Van Der Neut, Martin De Hann, Cornelis G. Kruse
-
Patent number: 8575148Abstract: This invention concerns spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein R1, R2, (R3)n, and (R4)m have the meanings given in the specification.Type: GrantFiled: December 10, 2009Date of Patent: November 5, 2013Assignee: Abbott Healthcare Products B.V.Inventors: Pieter Smid, Michael Mlinaric, Konrad F. Koehler, Sara Nuñez Garcia, Elmar Wegener, Josephus H. M. Lange
-
Patent number: 8563723Abstract: This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis.Type: GrantFiled: March 17, 2009Date of Patent: October 22, 2013Assignee: Abbott Healthcare Products, B.V.Inventors: Arnold Van Loevezijn, Wouter I. Iwema Bakker, Axel Stoit, Agatha A. M. Rensink, Jennifer Venhorst, Martina A. W. Van Der Neut, Martin De Haan, Cornelis G. Kruse
-
Patent number: 8389284Abstract: Polypeptides which are related to the neprilysin enzyme family and have zinc metalloprotease activities and are referred to as IGS5, polynucleotides encoding such polypeptides, vectors containing such polynucleotides, host cells containing such vectors, processes for producing such polypeptides and/or polynucleotides, screening methods for identifying compounds which stimulate or inhibit IGS5 polypeptides and/or polynucleotides, and the use of such polypeptides and/or polynucleotides in therapy of various dysfunctions, disorders or diseases, particularly cardiovascular diseases, metabolic diseases such as diabetes mellitus type II, and neurodegenerative disorders, such as Parkinson's Disease.Type: GrantFiled: May 25, 2011Date of Patent: March 5, 2013Assignee: Abbott Healthcare Products B.V.Inventors: Willy Deleersnijder, Yasmin Karimi-Nejad, Michael Weske, Dieter Ziegler
-
Patent number: 8062842Abstract: Methods and kits are provided for determining whether a subject is at risk of developing a neurological disease such as Alzheimer's disease and multiple sclerosis. The methods and kits are based on the detection of one or more nucleic acid variants in the MBL gene of the subject.Type: GrantFiled: June 10, 2008Date of Patent: November 22, 2011Assignee: Abbott Healthcare Products B.V.Inventors: Eugeen Vanmechelen, Lieve Nuytinck
-
Publication number: 20110262930Abstract: Polypeptides which are related to the neprilysin enzyme family and have zinc metalloprotease activities and are referred to as IGS5, polynucleotides encoding such polypeptides, vectors containing such polynucleotides, host cells containing such vectors, processes for producing such polypeptides and/or polynucleotides, screening methods for identifying compounds which stimulate or inhibit IGS5 polypeptides and/or polynucleotides, and the use of such polypeptides and/or polynucleotides in therapy of various dysfunctions, disorders or diseases, particularly cardiovascular diseases, metabolic diseases such as diabetes mellitus type II, and neurodegenerative disorders, such as Parkinson's Disease.Type: ApplicationFiled: May 25, 2011Publication date: October 27, 2011Applicant: Abbott Healthcare Products B.V.Inventors: Willy DELEERSNIJDER, Yasmin Karimi-Nejad, Michael Weske, Dieter Ziegler
-
Publication number: 20110237569Abstract: This invention concerns Spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein R1, R2, (R3)n, and (R4)m have the meanings given in the specification.Type: ApplicationFiled: December 10, 2009Publication date: September 29, 2011Applicant: ABBOTT HEALTHCARE PRODUCTS B.V.Inventors: Pieter Smid, Michael Mlinaric, Konrad F. Koehler, Sara Nunez Garcia, Elmar Wegener, Josephus H.M. Lange
-
Patent number: 8012471Abstract: Polypeptides which are related to the neprilysin enzyme family and have zinc metalloprotease activities and are referred to as IGS5, polynucleotides encoding such polypeptides, vectors containing such polynucleotides, host cells containing such vectors, processes for producing such polypeptides and/or polynucleotides, screening methods for identifying compounds which stimulate or inhibit IGS5 polypeptides and/or polynucleotides, and the use of such polypeptides and/or polynucleotides in therapy of various dysfunctions, disorders or diseases, particularly cardiovascular diseases, metabolic diseases such as diabetes mellitus type II, and neurodegenerative disorders, such as Parkinson's Disease.Type: GrantFiled: March 1, 2007Date of Patent: September 6, 2011Assignee: Abbott Healthcare Products B.V.Inventors: Willy Deleersnijder, Yasmin Karimi-Nejad, Michael Weske, Dieter Ziegler